Does 5-Amino-1MQ actually replace NAD+ therapy? Let's check

What's this video probably claiming?

Based on the caption asking whether 5-Amino-1MQ "replaces" NAD+, creator @coachcam.peps3 is almost certainly arguing that 5-Amino-1MQ, a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor, can serve as a superior or equivalent alternative to NAD+ precursor supplementation or IV NAD+ therapy. The framing of "replacement" is a classic peptide-content move: position the newer, less-understood compound as an upgrade over the more familiar one. The hashtags for "pep" and "medicine" signal this is squarely in the peptide-coaching space, where 5-Amino-1MQ has been gaining traction as a supposed metabolic and longevity optimizer. The creator likely walks through how NNMT inhibition affects NAD+ metabolism, possibly citing animal data on fat mass reduction or NAD+ tissue levels. This is a topic that sounds mechanistically coherent until you look at how thin the actual human evidence is.

What does the science actually show?

5-Amino-1MQ is a selective NNMT inhibitor. NNMT consumes SAM (S-adenosylmethionine) to methylate nicotinamide, producing 1-methylnicotinamide, which reduces NAD+ bioavailability in tissues. The logic is: block NNMT, spare NAD+, improve metabolic function. Hong et al. (2015, Biochemical Pharmacology) showed NNMT inhibition in mouse adipocytes reduced fat mass and improved insulin sensitivity. Neelakantan et al. (2018, Nature Communications) demonstrated that NNMT-knockout mice had lower adiposity. Those are real findings. But they are mouse studies using genetic knockouts or early-stage small molecules under tightly controlled lab conditions. There are no published Phase I or Phase II human clinical trials for 5-Amino-1MQ as of 2024. NAD+ precursors like NMN and NR, by contrast, have at least modest human trial data. Yoshino et al. (2021, Science) showed 250mg/day NMN improved muscle insulin signaling in postmenopausal women with prediabetes over 10 weeks. That is a low bar, but it exists. 5-Amino-1MQ does not clear it yet.

Where does the social media noise diverge from clinical reality?

The word "replace" is doing a lot of heavy lifting here, and that is where this content gets genuinely misleading. NAD+ precursor therapy and NNMT inhibition work through related but distinct pathways. NAD+ precursors increase substrate availability system-wide. NNMT inhibition reduces one specific drain on NAD+ pools, primarily in adipose tissue. Calling one a replacement for the other conflates mechanism with outcome. There is also a dosing and safety data vacuum around 5-Amino-1MQ in humans. Peptide coaches frequently extrapolate from rodent doses without acknowledging that metabolic scaling between species is not linear. The compound is not FDA-approved, not available through licensed pharmacies for this indication, and has no established therapeutic dosing range in humans. Content creators who imply it is a validated clinical tool rather than a research-stage molecule are misrepresenting the state of the evidence. The "classroom" framing used in the caption suggests a community of paying followers is receiving this information as clinical guidance, which raises additional concerns about how it is being applied.

What should you actually know?

If you are considering either NAD+ therapy or compounds like 5-Amino-1MQ, the evidence hierarchy matters. IV NAD+ has anecdotal clinical use in addiction medicine and some longevity clinics, but rigorous trial data are limited. Oral NMN and NR have small human trials behind them with modest but real findings. 5-Amino-1MQ has compelling preclinical biology but zero published human trials. That gap is not a technicality. It means nobody knows the correct dose, the safety profile in humans, the long-term effects, or even whether the tissue-level mechanism translates out of mouse adipocytes. The claim that it "replaces" NAD+ therapy is not supported by the evidence base that exists today. Anyone presenting it that way is getting ahead of the data. A regulated telehealth provider should be able to explain exactly what trial data supports any compound they discuss, and right now, that conversation for 5-Amino-1MQ is very short.